assumptions:
- ä¸€ç´šæ¶ˆé™¤å‹•åŠ›å­¸
- ç·šæ€§è›‹ç™½çµåˆï¼ˆç„¡é£½å’Œï¼‰
- ç©©æ…‹ä¸‹è›‹ç™½çµåˆå¹³è¡¡
- è‚è‡Ÿç‚ºä¸»è¦ä»£è¬å™¨å®˜
author: NSForge Demo
category: derived
clinical_context: ç”¨æ–¼èª¿æ•´é«˜åº¦è›‹ç™½çµåˆè—¥ç‰©ï¼ˆå¦‚ warfarinã€phenytoinï¼‰çš„åŠ‘é‡ï¼Œç‰¹åˆ¥é©ç”¨æ–¼ä½ç™½è›‹ç™½è¡€ç—‡æ‚£è€…
created_at: '2026-01-03T09:30:41.067180'
derivation_steps:
- Load formula 'clearance' from textbook
- Load formula 'clearance' from textbook
- "\U0001F4CB [ASSUMPTION] æ¶ˆé™¤é€Ÿç‡å¸¸æ•¸ k_e ç¯„åœé€šå¸¸ç‚º 0.01-0.5 hâ»Â¹ï¼Œå–æ±ºæ–¼è—¥ç‰©æ€§è³ªå’Œä»£è¬é€”å¾‘\n   Related:\
  \ k_e"
- "\U0001F52C [PHYSICAL] åˆ†ä½ˆå®¹ç© V_d å°æ–¼è¦ªè„‚æ€§è—¥ç‰©å¯èƒ½è¶…éé«”é‡ï¼Œè¡¨ç¤ºè—¥ç‰©å»£æ³›åˆ†ä½ˆæ–¼çµ„ç¹”ä¸­\n   Related: V_d"
- Load formula 'free_drug' from textbook
- "\U0001F3E5 [CLINICAL] è›‹ç™½çµåˆç‡ f_b ç¯„åœ 0-1ï¼Œé«˜åº¦çµåˆè—¥ç‰© (f_b > 0.9) å¦‚ warfarin éœ€æ³¨æ„è—¥ç‰©äº¤äº’ä½œç”¨\n\
  \   Related: f_b"
- "\U0001F4A1 [OBSERVATION] ç¸½æ¿ƒåº¦ C_total ç‚ºå¯¦é©—å®¤æ¸¬é‡å€¼ï¼Œä½†åªæœ‰æ¸¸é›¢è—¥ç‰©å…·æœ‰è—¥ç†æ´»æ€§\n   Related: C_total"
- Load formula 'effective_clearance' from textbook
- "\U0001F52C [PHYSICAL] å…§åœ¨æ¸…é™¤ç‡ CL_int åæ˜ è‚è‡Ÿé…µç´ çš„ä»£è¬èƒ½åŠ›ï¼Œå— CYP450 èª˜å°/æŠ‘åˆ¶å½±éŸ¿\n   Related: CL_int"
- "\U0001F3E5 [CLINICAL] æ¸¸é›¢åˆ†ç‡ f_u = 1 - f_bï¼Œä½ç™½è›‹ç™½è¡€ç—‡æ‚£è€… f_u å¢åŠ ï¼Œéœ€èª¿æ•´åŠ‘é‡\n   Related: f_u,\
  \ f_b"
- å°‡æ¸¸é›¢åˆ†ç‡å®šç¾©ä»£å…¥æœ‰æ•ˆæ¸…é™¤ç‡
- "\U0001F4A1 [OBSERVATION] ç•¶ f_b æ¥è¿‘ 1 æ™‚ï¼ˆé«˜åº¦è›‹ç™½çµåˆï¼‰ï¼Œæœ‰æ•ˆæ¸…é™¤ç‡è¶¨è¿‘æ–¼é›¶ï¼Œè—¥ç‰©åŠè¡°æœŸé¡¯è‘—å»¶é•·\n   Related:\
  \ f_b, CL_int\n   See step 11"
- "âš ï¸ [LIMITATION] æ­¤æ¨¡å‹å‡è¨­ç·šæ€§å‹•åŠ›å­¸ï¼Œé«˜æ¿ƒåº¦æ™‚å¯èƒ½å‡ºç¾è›‹ç™½çµåˆé£½å’Œç¾è±¡\n   Related: f_b\n   See step 11"
- 'æ±‚è§£æ¶ˆé™¤é€Ÿç‡å¸¸æ•¸ k_eï¼Œçµåˆä¸‰å€‹å…¬å¼


  ğŸ“ Notes: æ­¤å…¬å¼æ•´åˆäº†å…§åœ¨æ¸…é™¤ç‡ã€è›‹ç™½çµåˆç‡èˆ‡åˆ†ä½ˆå®¹ç©ä¸‰å€‹åƒæ•¸'
- "\U0001F52C [PHYSICAL] k_e èˆ‡ V_d æˆåæ¯”ï¼šåˆ†ä½ˆå®¹ç©å¤§çš„è—¥ç‰©ï¼ˆå¦‚è„‚æº¶æ€§è—¥ç‰©ï¼‰ï¼Œæ¶ˆé™¤é€Ÿç‡å¸¸æ•¸æœƒè¼ƒå°\n   Related: k_e,\
  \ V_d\n   See step 14"
- "\U0001F3E5 [CLINICAL] å¯ç”±æ­¤å…¬å¼è¨ˆç®—åŠè¡°æœŸ tÂ½ = ln(2)/k_eï¼Œç”¨æ–¼è‡¨åºŠçµ¦è—¥é–“éš”è¨­è¨ˆ\n   Related: k_e\n \
  \  See step 14"
derived_from:
- clearance
- free_drug
- effective_clearance
description: æ¶ˆé™¤é€Ÿç‡å¸¸æ•¸è€ƒæ…®å…§åœ¨æ¸…é™¤ç‡ã€è›‹ç™½çµåˆç‡èˆ‡åˆ†ä½ˆå®¹ç©çš„ç¶œåˆé—œä¿‚
expression: CL_int*(1 - f_b)/V_d
id: 37e9f2bb
limitations:
- ä¸é©ç”¨æ–¼éç·šæ€§å‹•åŠ›å­¸ï¼ˆå¦‚ phenytoin é«˜æ¿ƒåº¦ï¼‰
- æœªè€ƒæ…®è…è‡Ÿæ¸…é™¤
- å¿½ç•¥è…¸è‚å¾ªç’°
- è›‹ç™½çµåˆé£½å’Œæ™‚å¤±æº–
name: two_compartment_drug_pk
references:
- Goodman & Gilman's Pharmacology, Ch.2
- Clinical Pharmacokinetics, 5th Ed
- Applied Clinical Pharmacokinetics, 3rd Ed
tags:
- pharmacokinetics
- protein-binding
- clearance
- elimination
- two-compartment
variables:
  CL_int:
    description: ''
    unit: ''
  V_d:
    description: ''
    unit: ''
  f_b:
    description: ''
    unit: ''
verification_method: ''
verified: false
verified_at: null
version: 1.0.0
